| AIA | Adjuvant-Induced Arthritis |
| BCR | B-cell receptor |
| BTK | Bruton’s tyrosine kinase |
| cGVHD | Chronic graft versus host disease |
| CAIA | Collagen antibody-induced arthritis |
| CIA | Collagen-induced arthritis |
| CLL | Chronic lymphocytic leukemia |
| COVID-19 | Coronavirus Disease 19 |
| DAMA | Damage-associated molecular patterns |
| EAE | Experimental autoimmune encephalomyelitis |
| EGFR | Epidermal growth factor receptor |
| hPBMC | Human Peripheral Blood Mononuclear Cell |
| hWB | Human whole blood |
| IC | Immune complexes |
| MCL | Mantle cell lymphoma |
| MS | Multiple sclerosis |
| RRMS | Relapsing–Remitting Multiple Sclerosis |
| NTN | Nephrotoxic nephritis |
| NSCL | Non-Small Cell Lung Cancer |
| PAMA | Pathogen-associated molecular patterns |
| PCA | Passive cutaneous anaphylaxis |
| PD | Pharmacodynamics |
| PH | Pleckstrin homology domain |
| PK | Pharmacokinetics |
| RA | Rheumatoid arthritis |
| RMS | Relapsing multiple sclerosis |
| SAR | Structure–activity relationship |
| SH2/SH3 | Src homology 2/3 domain |
| SLE | Systemic lupus erythematosus |
| SLL | Small lymphocytic lymphoma |
| SYK | Spleen tyrosine kinase |
| TCIs | Targeted covalent inhibitors |
| TH | Tec homology domain |
| TK | Tyrosine kinase domain |
| TLRs | Toll-like receptors |
| WM | Waldenström’s macroglobulinemia |